Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals Limited announced the issuance of 3,000,000 unlisted options as part of a previously disclosed transaction. These securities are unquoted and not intended for quotation on the ASX, reflecting the company’s strategic financial maneuvers to support its ongoing operations and growth initiatives.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on developing and commercializing therapies for various medical conditions. The company is primarily engaged in creating treatments that address unmet medical needs, leveraging its expertise in drug repurposing and development.
Average Trading Volume: 1,111,771
Technical Sentiment Signal: Buy
Current Market Cap: A$165M
For a thorough assessment of PAR stock, go to TipRanks’ Stock Analysis page.